# FDA 483 - ten23 health Valais AG - February 28, 2024

Source: https://www.globalkeysolutions.net/records/483/ten23-health-valais-ag/c195eb48-c4e3-453a-ae5a-65a7cb9e397f

> FDA 483 for ten23 health Valais AG on February 28, 2024. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: ten23 health Valais AG
- Inspection Date: 2024-02-28
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
- Summary: The FDA inspected ten23 health Valais AG, a drug product manufacturer in Visp, Switzerland, and found significant deficiencies in aseptic processing, environmental monitoring, quality control, and CAPA effectiveness. Observations included inadequate procedures to prevent microbiological contamination, persistent mold issues in cleanrooms, and insufficient visual inspection qualification for drug products. These issues indicate a high risk of product contamination and quality control failures.

## Related Documents

- [483 - 2019-04-24](https://www.globalkeysolutions.net/records/483/ten23-health-valais-ag/63581208-7264-4919-ade7-fd1f2306a687)
- [483 - 2025-08-27](https://www.globalkeysolutions.net/records/483/ten23-health-valais-ag/83145e5a-a987-4b0c-b84f-5a2b02733371)

## Related Officers

- [Stelios C Tsinontides](https://www.globalkeysolutions.net/people/stelios-c-tsinontides/7e17edef-7b2b-4d80-a2bf-58bd4e4ff658)
- [Holly Brevig](https://www.globalkeysolutions.net/people/holly-brevig/68a8fca4-e80e-40f2-9ecc-4b4bcfcd8d1d)
- [investigator](https://www.globalkeysolutions.net/people/thuy-thanh-nguyen/8e2e9be6-8d27-45d9-a3b0-cf3e9a0eb3c4)

Company: https://www.globalkeysolutions.net/companies/ten23-health-valais-ag/7d69d8ad-acae-409b-8630-b4bf5911b613

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd